These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Treatment
19 results:

  • 1. Predictive significance of fgfr4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment.
    Ottaiano A; Santorsola M; Ianniello M; Ceccarelli A; Casillo M; Sabbatino F; Petrillo N; Cascella M; Caraglia F; Picone C; Perri F; Sirica R; Zappavigna S; Nasti G; Savarese G; Caraglia M
    J Transl Med; 2024 Apr; 22(1):379. PubMed ID: 38650006
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Insight into the design of fgfr4 selective inhibitors in cancer therapy: Prospects and challenges.
    Chen X; Huang Y; Chen B; Liu H; Cai Y; Yang Y
    Eur J Med Chem; 2024 Jan; 263():115947. PubMed ID: 37976704
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel fgfr4 inhibitors for the treatment of colorectal cancer.
    Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
    Eur J Med Chem; 2023 Nov; 259():115703. PubMed ID: 37556948
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the fgfr4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer.
    Agarwal S; Afaq F; Bajpai P; Kim HG; Elkholy A; Behring M; Chandrashekar DS; Diffalha SA; Khushman M; Sugandha SP; Varambally S; Manne U
    Mol Oncol; 2022 Apr; 16(8):1728-1745. PubMed ID: 35194944
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Microarray-based identification of differentially expressed genes associated with andrographolide derivatives-induced resistance in colon and prostate cancer cell lines.
    Quah SY; Wong CC; Wong HC; Ho KL; Abdul Manan N; Deb PK; Sagineedu SR; Stanslas J
    Toxicol Appl Pharmacol; 2021 Aug; 425():115605. PubMed ID: 34087331
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A novel prognostic risk score model based on immune-related genes in patients with stage IV colorectal cancer.
    Xu K; He J; Zhang J; Liu T; Yang F; Ren T
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33034614
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer.
    Hong CS; Sun EG; Choi JN; Kim DH; Kim JH; Ryu KH; Shim HJ; Hwang JE; Bae WK; Kim HR; Kim KK; Jung C; Chung IJ; Cho SH
    Cancer Sci; 2020 Sep; 111(9):3268-3278. PubMed ID: 32533590
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic colorectal cancer.
    Duplaquet L; Figeac M; Leprêtre F; Frandemiche C; Villenet C; Sebda S; Sarafan-Vasseur N; Bénozène M; Vinchent A; Goormachtigh G; Wicquart L; Rousseau N; Beaussire L; Truant S; Michel P; Sabourin JC; Galateau-Sallé F; Copin MC; Zalcman G; De Launoit Y; Fafeur V; Tulasne D
    Mol Cancer Ther; 2019 Jun; 18(6):1137-1148. PubMed ID: 30926633
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Forkhead box C1 promotes colorectal cancer metastasis through transactivating ITGA7 and fgfr4 expression.
    Liu J; Zhang Z; Li X; Chen J; Wang G; Tian Z; Qian M; Chen Z; Guo H; Tang G; Huang W; Tian D; Wang D; Nie Y; Fan D; Wu K; Xia L
    Oncogene; 2018 Oct; 37(41):5477-5491. PubMed ID: 29884889
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Combination of fgfr4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells.
    Jiang D; Li J; Li J; Wang M; Han C; Wang X; Zhao C; Ye Y
    Int J Oncol; 2017 Nov; 51(5):1611-1620. PubMed ID: 29048661
    [TBL] [Abstract] [Full Text] [Related]  

  • 11.
    Cho SH; Hong CS; Kim HN; Shin MH; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ
    Cancer Res Treat; 2017 Jul; 49(3):766-777. PubMed ID: 27857023
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.
    Ahmed MA; Selzer E; Dörr W; Jomrich G; Harpain F; Silberhumer GR; Müllauer L; Holzmann K; Grasl-Kraupp B; Grusch M; Berger W; Marian B
    Oncotarget; 2016 Oct; 7(43):69976-69990. PubMed ID: 27650548
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. FGF-1/-3/fgfr4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
    Bai YP; Shang K; Chen H; Ding F; Wang Z; Liang C; Xu Y; Sun MH; Li YY
    Cancer Sci; 2015 Oct; 106(10):1278-87. PubMed ID: 26183471
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal cancer Patients Treated with 5-FU and Radiation.
    Bohanes P; Rankin CJ; Blanke CD; Winder T; Ulrich CM; Smalley SR; Rich TA; Martensen JA; Benson AB; Mayer RJ; Cripps CM; Danenberg K; Makar KW; Zhang W; Benedetti JK; Lenz HJ
    Clin Cancer Res; 2015 Apr; 21(7):1583-90. PubMed ID: 25589620
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. fgfr4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer.
    Liu R; Li J; Xie K; Zhang T; Lei Y; Chen Y; Zhang L; Huang K; Wang K; Wu H; Wu M; Nice EC; Huang C; Wei Y
    Cancer Res; 2013 Oct; 73(19):5926-35. PubMed ID: 23943801
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
    Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
    Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
    Desnoyers LR; Pai R; Ferrando RE; Hötzel K; Le T; Ross J; Carano R; D'Souza A; Qing J; Mohtashemi I; Ashkenazi A; French DM
    Oncogene; 2008 Jan; 27(1):85-97. PubMed ID: 17599042
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma.
    Morimoto Y; Ozaki T; Ouchida M; Umehara N; Ohata N; Yoshida A; Shimizu K; Inoue H
    Cancer; 2003 Nov; 98(10):2245-50. PubMed ID: 14601095
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Survival after repeat hepatic resection for recurrent colorectal metastases.
    Chiappa A; Zbar AP; Biella F; Staudacher C
    Hepatogastroenterology; 1999; 46(26):1065-70. PubMed ID: 10370668
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.